Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Onyx Pharmaceuticals Inc.

Division of Amgen Inc.
www.onyx-pharm.com

Latest From Onyx Pharmaceuticals Inc.

Bayer’s Stivarga First Drug To Enter Brain Cancer Platform Trial

GBM AGILE is the first global adaptive clinical trial platform for glioblastoma and the German group's liver and colorectal cancer drug will be the first of several therapies to be studied.

Cancer Clinical Trials

Amgen's Oncology Strategy: Building A Pipeline Of Novel Paradigm-Changing Drugs

Amgen oncology development VP Greg Friberg talked to Scrip about the company's rapidly growing oncology portfolio. "This is our renaissance," he said.

Cancer Research and Development Strategies

Amgen, Astellas Bring Tally Of US Charity Co-Pay Kickback Settlements To Eight

Astellas to pay $100m and Amgen to pay $24.75m to resolve allegations they paid Medicare copays for their products through copay assistance foundations.

Legal Issues Enforcement

Multiple Myeloma: A Growth Market Set To Shrink As Revlimid Generics Hit

Despite several new entrants to the multiple myeloma market, Datamonitor Healthcare forecasts that drug sales between 2017 and 2026 will peak in 2022 when Revlimid generics hit the market. J&J's Darzalex will become the new best-seller, but generate a fraction of Revlimid's sales.

Business Strategies Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Amgen Inc.
  • Senior Management
  • Mark McClung, SVP, Chief Commercial Officer
    Barbara Klencke, MD, SVP, Dev.
  • Contact Info
  • Onyx Pharmaceuticals Inc.
    Phone: (650) 266-0000
    249 E. Grand Ave.
    South San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register